The House Agriculture Committee's FDA appropriations report, which has passed out of committee, contains several sections relevant to compounding, and the picture is mixed. The good news first: the report includes supportive language on DTE access, hormone compounding, veterinary compounding, and encourages FDA to appoint PCAC members with real compounding experience. Those are wins worth noting.
The concerning part is where the committee endorses FDA's recent actions to limit GLP-1 APIs used in compounded medications – language that bears the unmistakable fingerprints of Novo Nordisk and Eli Lilly. The report characterizes compounded GLP-1s as being “mass marketed as substitutes for approved therapies” and instructs FDA to work with Customs and Border Protection to block “substandard” GLP-1 API – framing that conflates legitimate, state-licensed compounding pharmacies with illegal gray market actors. That's a familiar tactic, and it's no less misleading for showing up in a congressional report.
This is report language, not enacted law, but it signals where some committee members stand and what priorities they're hearing from industry.